SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
World game at war: why some European nations have threatened a World Cup boycott 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
SHANGHAI, China, April 24, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, May 2nd, 2018 at 8:30am ET to discuss financial results for the full year ended December 31, 2017. On the call, Zai Lab’s senior management team will also provide the latest status update on the Company’s various development programs.
Investor Conference Call Details
Date: Wednesday, May 2nd, 2018
Time: 8:30am ET
Dial-In Details: 1-866-394-4355 (US); 1-314-888-4344 (International); 4006828609 (China)
Conference ID: 5836799
A live webcast and replay will be available on the Zai Lab investor website: http://ir.zailaboratory.com. Please note, on Monday, April 30th, 2018 Zai Lab intends to file its Form 20-F for the Year Ended December 31, 2017.
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.
Contact:
Zai Lab
Billy Cho
+86 137 6151 2501
[email protected]
Solebury Trout
John Graziano
+1 646 378 2942
[email protected]
